0 CHECKOUT

Global Infectious Diseases Partnering 2010-2016: Deal trends, players and financials

  • ID: 2190608
  • July 2016
  • Region: Global
  • 800 pages
  • CurrentPartnering
1 of 4

Global Infectious Diseases Partnering 2010 to 2016 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Infectious Diseases partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Infectious Diseases partnering agreement structure
Infectious Diseases partnering contract documents
Top Infectious Diseases deals by value
Most active Infectious Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Infectious Diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers

4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory

5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

Appendices

Appendix 1 - Directory of Infectious Diseases deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Infectious Diseases deals by deal type 2010 to 2016
Appendix 3 - Directory of Infectious Diseases deals by stage of development 2010 to 2016
Appendix 4 - Directory of Infectious Diseases deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Infectious Diseases partnering since 2010
Figure 2: Infectious Diseases partnering by deal type since 2010
Figure 3: Infectious Diseases partnering by industry sector since 2010
Figure 4: Infectious Diseases partnering by stage of development since 2010
Figure 5: Infectious Diseases partnering by technology type since 2010
Figure 6: Infectious Diseases partnering by indication since 2010
Figure 7: Infectious Diseases deals with a headline value
Figure 8: Infectious Diseases deals with upfront payment values
Figure 9: Infectious Diseases deals with milestone payment
Figure 10: Infectious Diseases deals with royalty rates
Figure 11: Active Infectious Diseases dealmaking activity- 2010 to 2016
Figure 12: Top Infectious Diseases deals by value since 2010

Note: Product cover images may vary from those shown
3 of 4

Global Infectious Diseases Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Infectious Diseases deal trends since 2010
Access Infectious Diseases deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Infectious Diseases partner companies
Comprehensive access to over 750 links to actual Infectious Diseases deals entered into by the world’s biopharma companies
Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Infectious Diseases opportunities
Uncover companies actively partnering Infectious Diseases opportunities

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.